GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hexima Ltd (ASX:HXL) » Definitions » Inventories, Raw Materials & Components

Hexima (ASX:HXL) Inventories, Raw Materials & Components : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Hexima Inventories, Raw Materials & Components?

Hexima's inventories, raw materials & components for the quarter that ended in Dec. 2023 was A$0.00 Mil.


Hexima Inventories, Raw Materials & Components Historical Data

The historical data trend for Hexima's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hexima Inventories, Raw Materials & Components Chart

Hexima Annual Data
Trend Jun08 Jun09 Jun10 Jun20 Jun21 Jun22 Jun23
Inventories, Raw Materials & Components
Get a 7-Day Free Trial - - - - -

Hexima Semi-Annual Data
Dec06 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Hexima Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Hexima (ASX:HXL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hexima Ltd (ASX:HXL) » Definitions » Inventories, Raw Materials & Components
Traded in Other Exchanges
N/A
Address
84-90 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Hexima Ltd is a biotechnology company. The company is engaged in the research and development of plant-derived proteins and peptides for applications as human therapeutics.